Department of Health Sciences and Technology, ETH Zürich, Schmelzbergstrasse 9, 8092 Zurich, Switzerland.
Int J Mol Sci. 2017 Oct 22;18(10):2212. doi: 10.3390/ijms18102212.
DNA is damaged on a daily basis, which can lead to heritable mutations and the activation of proto-oncogenes. Therefore, DNA damage and repair are critical risk factors in cancer, aging and disease, and are the underlying bases of most frontline cancer therapies. Much of our current understanding of the mechanisms that maintain DNA integrity has been obtained using antibody-based assays. The oligonucleotide equivalents of antibodies, known as aptamers, have emerged as potential molecular recognition rivals. Aptamers possess several ideal properties including chemical stability, in vitro selection and lack of batch-to-batch variability. These properties have motivated the incorporation of aptamers into a wide variety of analytical, diagnostic, research and therapeutic applications. However, their use in DNA repair studies and DNA damage therapies is surprisingly un-tapped. This review presents an overview of the progress in selecting and applying aptamers for DNA damage and repair research.
DNA 每天都会受到损伤,这可能导致遗传突变和原癌基因的激活。因此,DNA 损伤和修复是癌症、衰老和疾病的关键风险因素,也是大多数一线癌症疗法的基础。我们目前对维持 DNA 完整性的机制的理解很大程度上是通过基于抗体的检测获得的。抗体的寡核苷酸等价物,称为适体,已成为潜在的分子识别竞争对手。适体具有包括化学稳定性、体外选择和批次间变异性缺失在内的几个理想特性。这些特性促使适体被广泛应用于分析、诊断、研究和治疗应用。然而,它们在 DNA 修复研究和 DNA 损伤治疗中的应用却令人惊讶地未被开发。这篇综述介绍了用于 DNA 损伤和修复研究的适体的选择和应用的进展概述。